Introduction
============

The secretory pathway is permanently challenged by large amounts of newly synthesized proteins and lipids that need to be correctly sorted and transported. The first transport step is initiated by the incorporation of secretory proteins into COPII (coat protein II)-coated vesicles budding from the ER ([@bib8]; [@bib26]). COPII coat assembly starts by activation of the small GTPase Sar1 by its exchange factor Sec12. Active Sar1 on ER membranes mediates the recruitment of the COPII subunits Sec23-Sec24 and Sec31-Sec13, which induces COPII vesicle budding. In mammalian cells, COPII vesicles form at ribosome-free transitional elements of the rough ER, termed ER exit sites (ERESs; [@bib32]; [@bib51]). Thus, COPII proteins are faithful markers for ERESs. Sec16 also localizes to ERESs and plays a central role in the organization of ERESs and COPII vesicle biogenesis ([@bib46]; [@bib47]; [@bib6]; [@bib18]; [@bib13]).

In mammals, COPII vesicles mediate cargo transport to the ER--Golgi intermediate compartment (ERGIC), where decisions are made either to recycle proteins back to the ER via COPI vesicles or to transport them on to the Golgi ([@bib2]). Retrograde transport from Golgi to ER is also mediated by COPI vesicles ([@bib27]) and involves passage through the ERGIC, at least partially. Thus, the ERGIC is an intermediary station in bidirectional ER--Golgi trafficking.

In contrast to the advanced knowledge of the mechanisms underlying vesicular trafficking, it remains largely unknown to what extent the secretory pathway is regulated by cellular signaling pathways. A limited number of kinases and phosphatases have been implicated in the regulation of the early secretory pathway ([@bib21]; [@bib33]; [@bib4]), but detailed understanding of the high-order regulation calls for a systematic approach.

Results
=======

Kinases and phosphatases regulating the early secretory pathway
---------------------------------------------------------------

To identify genes regulating the ER--Golgi system, we used an siRNA-based knockdown approach targeting all human kinases and phosphatases for effects on the localization of ERGIC-53, a sensitive marker for changes in trafficking and morphology of the early secretory pathway ([@bib41]; [@bib24]). The screen was performed in HeLa cells stably expressing GFP-tagged ERGIC-53 ([@bib5]). Because of its cycling, the type I transmembrane protein ERGIC-53 is a sensitive indicator for both changes in bidirectional traffic in the secretory pathway and organelle integrity.

Cells were transfected with three siRNAs (not pooled) to each of the 916 known and putative protein and lipid kinases and phosphatases (724 kinases; 192 phosphatases; [Table S1](http://www.jcb.org/cgi/content/full/jcb.200912082/DC1)). Transfection efficiency was \>80% on average, and down-regulation was \>70% when tested on various selected proteins. All siRNAs had nonoverlapping sequences. 48 h after transfection, cells were fixed and stained with DAPI/Syto42 to label nuclei and cytoplasm, providing information on cell number. Images were acquired by automated spinning disk confocal microscopy. 16 frames/well were acquired for each GFP--ERGIC-53 and DAPI/Syto42. Images were analyzed visually. Kinases/phosphatases were chosen for further analysis if two out of three siRNAs affected the pattern of ERGIC-53. Kinases/phosphatases were excluded if silencing either compromised cell viability (i.e., strong reduction in cell number) or had previously been reported to induce apoptosis in an siRNA screen in HeLa cells ([@bib29]).

Our primary screen retrieved 154 kinases/phosphatases hits. To validate them in a secondary screen, endogenous ERGIC-53 was covisualized with markers for ERESs (Sec31) and Golgi (giantin) by double immunofluorescence microscopy. 122 of the original 154 hits were validated as true positive (∼79%; [Table S2](http://www.jcb.org/cgi/content/full/jcb.200912082/DC1)), of which ∼12% were phosphatases. 56% belonged to one of the eight kinase classes ([Fig. 1 A](#fig1){ref-type="fig"}). The remainder (∼32%) belonged to the group of atypical, putative, or uncharacterized kinases and regulatory subunits. Overall, ∼8% (16 out of 193) of the phosphatome library and ∼15% (106 out of 723) of the kinome library were true hits. Importantly, based on screening various databases and the literature, we conclude that at least 118 out of the 122 identified kinases and phosphatases are expressed in HeLa cells (Table S2).

![**Classification of kinase/phosphatase hits.** (A) Assignment to protein families. TKL, Tyr kinase--like; STE, related to sterile kinases; CK1, casein kinase 1; AGC, kinase family containing PKA, PKG, and PKC; CAM kinase, calmodulin kinases; CMGC, kinase family containing CDK, MAPK, GSK, and CKL. (B) Phenotypic classification of hits. (C--F) Immunofluorescence of phenotypes. HeLa cells transfected with control siRNA (C) or siRNA to MAPK4 (example of the ER class; D), SCYL1 (example for the mixed class; E), and MAPK14 (example for the Golgi class; F) are shown. Cells were fixed 72 h after transfection and double stained with antibodies against the indicated proteins. Bars, 10 µm.](JCB_200912082_RGB_Fig1){#fig1}

Hits were phenotypically grouped ([Fig. 1 B](#fig1){ref-type="fig"}). The ER class comprises all hits with enhanced ER staining of ERGIC-53 and with reduction of peripheral ERGIC clusters ([Fig. 1](#fig1){ref-type="fig"}, compare C with D; and Table S2). ERES number was reduced, but the Golgi was unchanged. The Golgi class comprises all hits with fragmented or tubulated Golgi. Peripheral ERGIC clusters and ERESs were unaffected, but juxtanuclear ERGIC was lost ([Fig. 1 F](#fig1){ref-type="fig"} and Table S2). The overall microtubule organization was unaffected (Table S2). The mixed class includes all kinases/phosphatases that did not fit into the ER or Golgi class. Our screen retrieved the known kinase regulators of intracellular trafficking, PCTAIRE1/PCTK1, MST4, PIK4CA, and SCYL1. Silencing PCTAIRE1/PCTK1 reduces the number of ERESs ([@bib33]), which is consistent with our finding that PCTK1 is an ER-class hit exhibiting a reduced number of peripheral ERGIC punctae (Table S2) and ERESs. Silencing MST4 disrupts Golgi morphology ([@bib35]). In our screen, we identified MST4 as a Golgi-class hit with fragmented Golgi (Table S2). We previously showed that a knockdown of PIK4CA (PI4-kinase IIIα) affects ERES number and ERES adaptation to cargo load ([@bib13]). In the current screen, PIK4CA was identified as a mixed-class hit with a reduced number of peripheral ERGIC punctae (Table S2) and slight fragmentation of the Golgi (not depicted). Finally, SCYL1 has been shown to bind COPI and to be involved in retrograde Golgi to ER transport ([@bib9]). In the current work, SCYL1 appeared as a mixed-class hit that reduced the number of peripheral ERGIC punctae (Table S2) and tubulated the Golgi ([Fig. 1 E](#fig1){ref-type="fig"}). Thus, besides the few known kinases, our screen identified a large number of novel potential regulators of the early secretory pathway.

Functional predictions from network analysis
--------------------------------------------

ER- and Golgi-class hits were assembled into a network using the STRING database (<http://string.embl.de/>; [@bib20]). ER-class hits were well connected ([Fig. 2 A](#fig2){ref-type="fig"}), whereas Golgi-class hits were not ([Fig. 2 B](#fig2){ref-type="fig"}). The connectivity of ER-class hits enabled us to perform functional annotation clustering using the DAVID database (<http://david.abcc.ncifcrf.gov/>; [@bib17]). We searched for specific enrichment of our hits within signaling pathways. ER-class hits were associated with 13 different pathways. Nine ER-class hits were annotated to the MAPK pathway ([Fig. 2 C](#fig2){ref-type="fig"}). The mitogenic and the stress signaling pathways involving MAPKs are illustrated in [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.200912082/DC1). Interestingly, the mitogenic MAPK signaling pathway only included ER-class hits. Lipid kinases were over-represented (26% of the lipid kinome vs. 14% of the protein kinome), which is consistent with the fact that we are studying membrane trafficking. The phosphatidylinositol and inositol phosphate metabolism was specifically associated with ER- and mixed-class hits ([Fig. 2 C](#fig2){ref-type="fig"} and Fig. S1 B). This is consistent with the notion that phosphatidylinositol-modifying kinases may play a role in ER export ([@bib7]; [@bib13]).

![**Network of kinase hits indicates a role for MAPK signaling in the regulation of ER export.** (A) All ER-class hits were assembled into a network using the STRING database. (B) Assembly of all of the Golgi-class hits into a network using the STRING database. Edges in both networks indicate an interaction that is experimentally verified or an association into a signaling pathway. (C) ER-, mixed-, and Golgi-class hits specifically enriched in signaling pathways deduced from the DAVID database.](JCB_200912082_RGB_Fig2){#fig2}

We also wondered whether our collection of Golgi-class hits contains signatures of signaling pathways or cellular processes. This issue cannot be addressed with the same approach used for the analysis of the ER-class hits because Golgi-class hits are associated with only one signaling pathway ([Fig. 2 C](#fig2){ref-type="fig"}). This difference is explainable by poor hit connectivity, which does not allow functional annotation clustering using the DAVID database ([Fig. 2 B](#fig2){ref-type="fig"}) and thus calls for an alternative approach. We used a recently described new way of anchored network construction ([@bib50]). The rationale of this approach is to anchor the Golgi-class hits to known proteins involved in Golgi structure and biology. We used several anchor proteins. The Golgi matrix protein GM130 (GOLGA2) was chosen because of its well accepted role in Golgi structural maintenance. Moreover, GM130 was shown to interact with the Golgi-class hit MST4 ([@bib35]). We also used the cargo receptor p24-α (TMED2) and the GTPase Arf1. Both proteins play important roles in Golgi biology and bidirectional ER to Golgi trafficking. Because the Golgi is known to play an important role in cell polarity, we constructed a multianchored network with the known polarity regulators Par3 (PARD3), Par6 (PARD6A), PKC-ζ (PRKCZ), Scrib, Pals1 (MPP5), and Cdc42 ([Fig. 3 A](#fig3){ref-type="fig"}). Four networks were established, each of which connected all Golgi-class hits. The four networks were then merged by generating a union using the Cytoscape software and analyzed using the BiNGO plugin ([Fig. 3 A](#fig3){ref-type="fig"}). BiNGO detects specific enrichment of Gene Ontology (GO) annotations for cellular processes. To test for the enrichment of signaling pathways, we analyzed the merged network using the DAVID database. Several signaling pathways and cellular processes were enriched (Fig. S1 C). By combining the BiNGO and DAVID analyses, we note possible links between Golgi structure and apoptosis, proliferation, cell size, and infection. Golgi positioning was previously shown to also play an important role in directional cell migration ([@bib49]). However, the focus of previous studies was on structural proteins of the Golgi ([@bib38]; [@bib49]). We asked whether Golgi-class hits regulate cell migration. Indeed, in a scratch wound assay, the knockdown of various Golgi-class members impaired correct position of the Golgi and wound healing ([Fig. 4](#fig4){ref-type="fig"}). Thus, besides revealing signaling pathways associated with ER hits, our study provides a resource of signaling molecules that regulate Golgi shape and thereby cell migration.

![**BiNGO analysis of Golgi-class hits from four anchored networks.** (A) Four networks were generated with the Golgi-class hits anchored to GOLGA2, TMED2, ARF1, and polarity regulators (Par3, Par6, Cdc42, Pasl1, PKC-ζ, and Scrib). Networks were merged using the Cytoscape software and analyzed using the BiNGO 2.3 plugin. GO term cellular processes were scored at a significance value of at least 0.001. The Benjamini-Hochberg false discovery rate correction was used. (B) The network of cellular processes displayed in a hierarchical layout. Large PDF versions of these networks and their underlying data (which can be opened and visualized in Cytoscape) can be found in the online supplemental material.](JCB_200912082_RGB_Fig3){#fig3}

![**Kinases and phosphatases of the Golgi class inhibit orientation of the Golgi toward a scratch wound.** HeLa cells were transfected with siRNAs to the indicated genes. After 72 h, a scratch wound was introduced. 6 h later, cells were fixed and stained for giantin to label the Golgi. (A) Representative images. (B) Quantification of two experiments with at least 35 cells each displayed as the percentage of cells exhibiting Golgi orientation to and away from the wound. (C) 48 h after the indicated knockdown, a wound was introduced, and cells were fixed 24 after later. Cells were labeled with FITC-tagged Con A. Note that STYX and AKAP28 knockdown cells fail to close the wound, in contrast to control cells. (A and C) White lines indicate the position of the scratch. Bars: (A) 10 µm; (C) 200 µm.](JCB_200912082_GS_Fig4){#fig4}

The MAPK pathway regulates ERESs and ER exit
--------------------------------------------

Because numerous ER-class hits are members of the MAPK pathway, we asked whether the MAPK pathway affects ERESs. To determine the range within which ERESs can be regulated in our experimental systems, we silenced Sec16, a key regulator of ERESs. Knockdown of Sec16 maximally reduces ERES number by 50% ([Fig. 5 A](#fig5){ref-type="fig"}; [@bib13]). If the MAPK pathway regulates ERESs, its hyperactivation should increase, whereas its inhibition should decrease ERES number. This was indeed observed. Silencing NF1 (neurofibromin 1), which hyperactivates the MAPK pathway ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.200912082/DC1)), increased the number of ERESs by ∼20% ([Fig. 5 A](#fig5){ref-type="fig"}). In contrast, silencing ERK2 (an ER-class hit) but not ERK1 significantly reduced the number of ERESs by ∼30% ([Fig. 5 A](#fig5){ref-type="fig"}). Thus, the full range by which the MAPK pathway can regulate ERES number is ∼50%. Knockdown of ERK2 did not affect the levels of ERK1 ([Fig. 5 B](#fig5){ref-type="fig"}), indicating that the effect of ERK2 silencing was specific. To further support this, we performed rescue experiments with Flag-tagged rat ERK2, which is not recognized by the siRNA to human ERK2. Cells were transfected with control or ERK2 siRNA and processed for ERES analysis 72 h later. In the rescue experiment, the Flag-tagged rat ERK2 cDNA was transfected 24 h before ERES analysis. [Fig. 5 C](#fig5){ref-type="fig"} shows that the Flag-tagged rat ERK2 can reincrease the number of ERESs, very much in contrast to a kinase-dead version of ERK2 (ERK2-K52R).

![**A role for MAPK signaling in the regulation of ERES number and ER to Golgi transport.** (A) HeLa cells were transfected with the indicated siRNAs and fixed after 72 h. Anti-Sec31--labeled ERESs were quantified (means ± SD; *n* = 3). Asterisks indicate statistically significant differences (\*, P \< 0.05) from control (unpaired *t* test). (B) Cells were transfected with control or ERK2 siRNA. After 72 h, cells were lysed, and ERK1/2 was detected by immunoblotting. (C) HeLa cells were transfected with control or ERK2 siRNA (siERK2). After 48 h, the ERK2 siRNA--treated cells were left untreated (mock) or were transfected with Flag-tagged ERK2 cDNA or Flag-tagged ERK2-K52R cDNA. Cells were fixed 24 h later and stained for Flag and Sec31, and ERESs were counted. Asterisks indicate statistically significant differences (\*, P \< 0.05). (D) ER--Golgi transport of endogenous transferrin receptor was measured 72 h after transfection with the indicated siRNAs. Cells were subjected to pulse-chase experiments with \[^35^S\]Met. Transferrin receptor was immunoprecipitated, treated with Endo H, separated by SDS-PAGE, and visualized by autoradiography. C0 and C30: control siRNA transfected and chased for 0 min and 30 min, respectively. ERK2: knockdown cells chased for 30 min. The bar diagram shows means ± SD (*n* = 3). The asterisk indicates statistically significant difference (\*, P \< 0.05) from control (unpaired *t* test). (E) ER--Golgi transport of endogenous α1-antitrypsin in HepG2 cells. 2 d after plating, cells were subjected to pulse-chase experiments with \[^35^S\]Met. Cells were treated with DMSO (C) or the MEK inhibitor PD98059 (+PD) for 30 min before the pulse. Cells were pulsed for 10 min and chased for 15 min. C0 and C15: DMSO-treated cells chased for 0 min and 15 min, respectively. +PD: PD98059-treated cells chased for 15 min. The bar diagram is an evaluation of two independent experiments. (B, D, and E) The black lines on the blot indicate the position of the 50-kD (B and E) or 75-kD (D) molecular mass marker.](JCB_200912082_GS_Fig5){#fig5}

Next we tested whether the decrease in the number of ERESs translates into an effect on ER to Golgi transport. Silencing of ERK2 indeed reduced ER to Golgi transport of endogenous transferrin receptor in HeLa cells ([Fig. 5 D](#fig5){ref-type="fig"}). Because ERGIC-53 was used as a readout in our screen, we also tested transport of the ERGIC-53 cargo protein α1-antitrypsin. Inhibition of the MAPK pathway by PD98059 reduced transport of α1-antitrypsin ([Fig. 5 E](#fig5){ref-type="fig"}).

The MAPK pathway is regulated by scaffolds ([@bib25]). Our library included the CNK1 (connector enhancer of the kinase suppressor of Ras-1) and the kinase suppressor of Ras-1 and -2. In addition, MEKK1 is also thought to act as a scaffold ([@bib22]). In our screen, CNK1 and MEKK1 were ER-class hits. Knockdown of CNK1 ([Fig. 5 A](#fig5){ref-type="fig"}) and MEKK1 (not depicted) reduced the number of ERESs. The effect of CNK1 was weak, but this was to be expected because CNK1 knockdown does not completely block the MAPK pathway but rather flattens the response curve to mitogens (Fig. S2 B). As expected for a scaffold, overexpression of HA-tagged CNK1 also had a negative effect and thus reduced ERES number ([Fig. 5 A](#fig5){ref-type="fig"}). Collectively, these results show that the Raf--MEK (MAPK/ERK \[extracellular signal-regulated kinase\] kinase)--ERK pathway, via ERK2, regulates the number of ERESs and ER to Golgi transport.

ERK2 stimulates COPII vesicle budding
-------------------------------------

Does ERK2 affect the biogenesis of transport vesicles? We used an established in vitro COPII vesicle budding assay to address this question ([@bib23]). HeLa microsomes were incubated with ERK2-depleted HeLa cytosol, ATP-regenerating system, and GTP for 30 min at 25°C, and the appearance of ERGIC-53 in the vesicle fraction was monitored. The addition of purified ERK2 to the reaction mixture increased the amount of ERGIC-53 in the vesicle fraction ([Fig. 6](#fig6){ref-type="fig"}), indicating that ERK2 stimulates the formation of COPII vesicles at the ER. Our budding assay truly measures COPII vesicle production because depletion of Sec24A+B from the cytosol affected incorporation of ERGIC-53 into vesicles ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.200912082/DC1)). We showed previously that ER export of ERGIC-53 is dependent on these Sec24 isoforms ([@bib48]).

![**ERK2 stimulates COPII vesicle budding.** HeLa microsomes were incubated for 30 min with ATP and an ATP-regenerating system, GTP, and cytosol of ERK2-silenced HeLa cells in the presence or absence of purified ERK2. COPII vesicles (V) were collected by centrifugation and immunoblotted for anti--ERGIC-53 and anti--CLIMP-63 (ER marker). The asterisk represents a statistically significant difference (\*, P \< 0.05; paired *t* test). Error bars indicate ±SD. M, 33% microsome input.](JCB_200912082_GS_Fig6){#fig6}

Sec16 is a target of the Raf--MEK--ERK signaling pathway
--------------------------------------------------------

Sec16 is a key regulator of ERES biogenesis and maintenance, making it a prime candidate for an ERK2 target. We first assessed whether the MAPK pathway affects the in vivo dynamics of Sec16. This is best probed by FRAP of individual ERESs labeled by GFP-tagged Sec16. As shown in [Fig. 7 A](#fig7){ref-type="fig"}, GFP-Sec16 (National Center for Biotechnology Information Protein accession number [O15027](O15027)) nicely recovered after photobleaching of control cells as opposed to ERK2-silenced cells or cells in which the MAPK pathway was pharmacologically blocked. This is also illustrated by the significantly higher mobile fraction of Sec16 under control conditions ([Fig. 7 B](#fig7){ref-type="fig"}). In addition, we compared fluorescence recovery in serum-starved cells and cells treated with EGF (for 10 min). Treatment with EGF enhanced fluorescence recovery of Sec16 ([Fig. 7 C](#fig7){ref-type="fig"}) and increased the mobile fraction of Sec16 ([Fig. 7 D](#fig7){ref-type="fig"}). The change in mobility of Sec16 also translated into a change in the mobility of downstream COPII components. Treatment with EGF increased the recovery and mobile fraction of YFP-tagged Sec24D ([Fig. 7, E and F](#fig7){ref-type="fig"}). Because Sec16 responds to alterations of the MAPK pathway, it is a likely ERK2 target.

![**Changes in Sec16 dynamics upon inhibition or activation of the MAPK pathway.** (A) Cells were transfected with control siRNA or siRNA to ERK2. After 48 h, cells were transfected with GFP-Sec16 cDNA, and 24 h later, FRAP analysis was performed. Of the two control siRNA--transfected cells, one dish was treated with solvent (control) and one with the MEK inhibitor PD98059 for 30 min before analysis. The right panel shows examples of bleached ERESs with indicated time points. (B) Quantification of mobile fractions from the curves in A (see Materials and methods). Asterisks indicate statistically significant differences (means ± SD; three independent experiments; \*, P \< 0.01; unpaired *t* test). (C) HeLa cells expressing GFP-Sec16 were serum starved for 8 h before the FRAP experiment (WT-ut). Afterward, cells were treated with EGF for 10 min, and further FRAP curves were recorded from the same dish (WT+EGF). (D) Quantification of mobile fractions from the curves in C (see Materials and methods; means ± SD; three independent experiments, four curves each; paired *t* test). (E) HeLa cells expressing YFP-Sec24D were serum starved for 8 h before the FRAP experiment (Sec24D-ut). Afterward, cells were treated with EGF for 10 min, and additional FRAP curves were recorded from the same dish (Sec24D+EGF). (F) Quantification of mobile fractions from the curves in E (see Materials and methods; means ± SD; three independent experiments, four curves each; paired *t* test). Bar, 1 µm.](JCB_200912082_RGB_Fig7){#fig7}

We monitored whether Sec16 is phosphorylated on a Ser/Thr-Pro sequence using a MAPK substrate antibody. This would be expected if Sec16 was an ERK target. GFP-Sec16 was immunoprecipitated, subjected to SDS-PAGE, and immunoblotted with antibodies to Sec16. The blots were stripped and reprobed with antibodies to a phosphorylated MAPK substrate. If Sec16 is phosphorylated on a MAPK target sequence, a band should appear at the same position as the Sec16 band before stripping. This was indeed observed. [Fig. 8 A](#fig8){ref-type="fig"} shows that Sec16 was phosphorylated on a MAPK target sequence, and this phosphorylation diminished when cells were cultured in the absence of mitogens (that is, in serum-free medium). Because Sec24D also responded to EGF treatment in our FRAP assay, we tested whether Sec24D is also recognized by the MAPK substrate antibody. However, this was not the case (unpublished data). This result indicates that the change in the mobility of Sec24D is not caused by phosphorylation by the MAPK pathway. Most likely, the increase of Sec24D mobility is indirectly induced by Sec16.

![**Sec16 is a target of the MAPK pathway.** (A) Cells were transfected with GFP-Sec16 cDNA. After 8 h, medium was replaced by complete medium (Cont) or medium without serum (starved). Sec16 was immunoprecipitated with anti-GFP, subjected to SDS-PAGE, and immunoblotted with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate (bottom). The numbers above the blot indicate relative amounts determined by densitometric scanning. The intensity of the MAPK substrate band was normalized to the Sec16 band. To facilitate comparisons, the value of the control band was set to 1. Note that starvation reduces phosphorylation of Sec16 by 40% (means ± SD; three independent experiments; P \< 0.05). (B) Cells were transfected with GFP-Sec16 and, after 8 h, serum starved. Sec16 was immunoprecipitated with anti-GFP. A parallel cell culture was treated with EGF. Active ERK was immunoprecipitated with agarose-coupled anti--phospho-ERK and incubated with the immunoprecipitated active ERK. Immunoprecipitated GFP-Sec16 and immunoprecipitated phospho-ERK were mixed, and the kinase reaction was performed for 30 min at 30°C (reaction). 50% of the reaction was separated by SDS-PAGE and immunoblotted with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate (bottom). (C) Cells were transfected with GFP-Sec16 cDNA (wild type \[wt\] or T415I). Immunoprecipitated Sec16 (anti-GFP) was coincubated with active ERK2 and ATP for 30 min at 30°C. 50% of the reaction was loaded, subjected to SDS-PAGE, and immunoblotted with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate antibody (bottom). The numbers above the blot indicate relative amounts determined by densitometric scanning. The intensity of the MAPK substrate band was normalized to the Sec16 band. To facilitate comparisons, the value of the control band was set to 1. Note that the mutation of T415I reduces the ability of ERK2 to phosphorylate Sec16 by at least 65% (means ± SD; three independent experiments). (D) Phosphorylation of purified GST-tagged Elk1 by immunoprecipitated phospho-ERK1/2 (IP p-ERK) as described in B or recombinant active ERK2 (rec. ERK2). The reaction was performed at 30°C for 30 min either with buffer (−) or with the kinase (+). (E) HeLa cells were transfected with a plasmid encoding GFP-Sec16 lacking the N-terminal 923 aa. Sec16 was immunoprecipitated with anti-GFP and incubated with active ERK2 and ATP for 30 min at 30°C. Samples were subjected to SDS-PAGE and immunoblotting with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate antibody (bottom). The arrow indicates the position where a band would be expected in case of corresponding phosphorylation. (F) HeLa cells expressing GFP-tagged truncation mutant of Sec16 lacking the N-terminal 923 aa (delta) were serum starved for 8 h before the FRAP experiment (delta-ut). Afterward, cells were treated with EGF for 10 min, and further FRAP curves were recorded from the same dish (delta+EGF). (G) Quantification of the mobile fractions from the curves in F (see Materials and methods; means ± SD; three independent experiments). (H) Cells were transfected with GFP-Sec16 cDNA (wild type \[wt\] or T415I). Sec16 was immunoprecipitated with anti-GFP, subjected to SDS-PAGE, and immunoblotted with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate (bottom). The numbers above the blot indicate relative amounts determined by densitometric scanning. The intensity of the MAPK substrate band was normalized to the Sec16 band. To facilitate comparisons, the value of the control band was set to 1. Note that the T415I mutation reduces the phosphorylation of Sec16 down to 30% (means ± SD; four independent experiments). (I) HeLa cells expressing GFP-tagged Sec16-T415I were serum starved for 8 h before the FRAP experiment (T415I-ut). Thereafter, the cells were treated with EGF for 10 min, and additional FRAP curves were recorded from the same dish (T415I+EGF). (J) Quantification of the mobile fractions from the curves in I (see Materials and methods; means ± SD; three independent experiments). (A--E and H) Black lines on the blots indicate the position of the 250-kD (A--C), 50-kD (D), 150-kD (E), or 250-kD (H) molecular mass marker.](JCB_200912082_RGB_Fig8){#fig8}

To more directly test whether Sec16 is phosphorylated by ERK, we performed in vitro experiments. [Fig. 8 B](#fig8){ref-type="fig"} shows that immunoisolated GFP-Sec16 from serum-starved cells, which are not phosphorylated, can be phosphorylated by incubation with immunoprecipitated active ERK ([Fig. 8 B](#fig8){ref-type="fig"}). To exclude that Sec16 was phosphorylated by a nonspecific component in the phospho-ERK immunoprecipitate, we performed experiments with recombinant ERK2. Recombinant active ERK2 also phosphorylated Sec16 ([Fig. 8 C](#fig8){ref-type="fig"}). Of note, both immunoprecipitated phospho-ERK and recombinant active ERK2 were active under our assay conditions as they were able to phosphorylate Elk1, a well known ERK target ([Fig. 8 D](#fig8){ref-type="fig"}).

In a next series of experiments, we attempted to identify the phosphorylation site or sites in Sec16 targeted by ERK2. A Sec16 mutant lacking the first 923 aa (Sec16-Δ923) still correctly localizes to ERESs ([@bib6]). This offers the possibility to test whether the phosphorylation site is located within the first 923 aa of Sec16. Sec16-Δ923 was not phosphorylated by ERK2 ([Fig. 8 E](#fig8){ref-type="fig"}) and, unlike wild-type Sec16, its mobility on ERESs did not respond to EGF treatment in the FRAP experiment ([Fig. 8, E and F](#fig8){ref-type="fig"}). This indicates that the phosphorylation site is likely located within the N-terminal 923 residues. Searching the amino acid sequence by Scansite (<http://scansite.mit.edu/>) revealed T415 as the most probable ERK target. We mutated T415 to Ile (Sec16-T415I), which reduced the ability of recombinant active ERK2 to phosphorylate Sec16 by at least 60% ([Fig. 8 C](#fig8){ref-type="fig"}), without affecting Sec16 localization (not depicted). The residual signal is most likely caused by minor phosphorylation of other residues by ERK2 in vitro (according to Scansite, there are 27 theoretical Pro-dependent Ser or Thr sites in Sec16, 14 of which are within the N-terminal 923 aa). This conclusion is supported by the finding that, at steady-state, Sec16-T415I exhibited some remaining phosphorylation (10--30% of Sec16-WT) when immunoprecipitated from HeLa cells ([Fig. 8 H](#fig8){ref-type="fig"}). Like Sec16-Δ923, Sec16-T415I did not respond to EGF treatment in the FRAP experiment ([Fig. 8, I and J](#fig8){ref-type="fig"}), supporting the notion that T415 is an important site for the regulation of Sec16 by ERK signaling.

Next, we asked whether the mutation of Thr415 to Ile affects the number of ERESs. To this end, we overexpressed either GFP-tagged wild-type Sec16 ([Fig. 9 A](#fig9){ref-type="fig"}) or GFP-tagged Sec16-T415I ([Fig. 9 B](#fig9){ref-type="fig"}). After 24 h, ERESs were stained for Sec31 and quantified. We also determined the effect of the mutation on peripheral ERGIC structures by staining for ERGIC-53. Exogenous expression of Sec16 exerts a negative effect on ERESs if the level of expression is too high. Therefore, we compared cells with only moderate GFP (i.e., Sec16) levels. In addition, we only compared cells with similar expression levels of GFP-Sec16 constructs. For quantification, we determined the value of GFP fluorescence and normalized it by the area. The mean fluorescence values (in arbitrary units) of cells expressing GFP--ERGIC-53 and GFP--Sec16-T415I were 3.48 ± 1.08 and 3.57 ± 1.46, respectively (means ± SD; three independent experiments). Expression of GFP--Sec16-T415I reduced the number of both ERESs and peripheral ERGIC punctae ([Fig. 9 C](#fig9){ref-type="fig"}). Furthermore, ERGIC-53 exhibited a stronger ER pattern in cells expressing the mutant Sec16, reminiscent of the ER-class hits ([Fig. 9 B](#fig9){ref-type="fig"}). The degree of down-regulation of ERESs was comparable with that observed in ERK2 knockdown cells ([Fig. 5 A](#fig5){ref-type="fig"}).

![**Phosphorylation of Sec16 is linked to ERES number.** (A--C) Hells cells were transfected with cDNA encoding wild-type GFP-Sec16 (GFP--Sec16-wt; A) or GFP--Sec16-T415I (B), fixed 24 h later, and immunostained for Sec31 to label ERESs or ERGIC-53 to label the ERGIC. (C) The number of ERESs and peripheral ERGIC punctae was counted. The bar graph represents the number of punctae positive for Sec31 (ERES) or ERGIC-53 (ERGIC). The values determined in cells expressing GFP--Sec16-wt were set to 100% (means ± SD; three independent experiments; asterisks indicate statistically significant difference to GFP--Sec16-wt; \*, P \< 0.05; unpaired *t* test). (D) Cells were transfected with cDNA for GFP-Sec16 together with either wild-type H-Ras (Ras-wt) or M1--H-RasV12 (RasV12). Sec16 was immunoprecipitated with anti-GFP, subjected to SDS-PAGE, and immunoblotted with anti-Sec16 (top). The blot was stripped and reprobed with anti--MAPK substrate (bottom). The numbers above the blot indicate relative amounts determined by densitometric scanning. The intensity of the MAPK substrate band was normalized to the Sec16 band. To facilitate comparisons, the mean value of the samples transfected with wild-type Ras was set to one (mean ± SD; three independent experiments). The black line on the blot indicates the position of the 250-kD molecular mass marker. (E) Cells were transfected with cDNA for HA-tagged M1-RasV12. After 24 h, cells were fixed and costained for HA (RasV12) and Sec31. The bar graph shows ERESs/cell comparing cells expressing RasV12 or not (control; means ± SD; three independent experiments; asterisk indicates statistically significant difference; \*, P \< 0.05 from control; unpaired *t* test). Bars, 10 µm.](JCB_200912082_GS_Fig9){#fig9}

If Sec16 is a target of the MAPK pathway, its hyperactivation should increase the level of Sec16 phosphorylation. Such a hyperactivation can be achieved by expression of a constitutively active form of Ras (RasV12). We coexpressed GFP-Sec16 either with wild-type Ras or RasV12 linked to the ER (M1-RasV12). The ER version of RasV12 was previously shown to be a strong stimulator of the Raf--MEK--ERK pathway and cell growth ([@bib30]). Sec16 phosphorylation was more than twofold higher in cells expressing RasV12 than in cells expressing wild-type Ras ([Fig. 9 D](#fig9){ref-type="fig"}). In addition, RasV12-expressing cells had a higher number of ERESs ([Fig. 9 E](#fig9){ref-type="fig"}), thereby linking Sec16 phosphorylation to ERES number. We conclude that Sec16 is a new target of ERK2.

Discussion
==========

Genetic and biochemical analyses over the past three decades have provided profound understanding of the machineries mediating bidirectional ER--Golgi trafficking ([@bib39]; [@bib8]; [@bib26]), and considerable knowledge is available on organelle shape and proteomics ([@bib15]; [@bib16]; [@bib10]). What has almost entirely been lacking is an understanding of high-order regulation of the secretory pathway by cellular signaling pathways. A recent study reported that arrival of a cargo wave in the Golgi activates Src family kinases ([@bib36]). Although this is an example for an adaptive response, it does not address the regulation of the secretory pathway by signaling under basal conditions.

Our siRNA screen provides a global view of kinase/phosphatase signaling to the early secretory pathway. Our key findings are as follows: (a) at least 122 kinases and phosphatases control the organization and/or traffic of the ER--Golgi system; (b) the Raf--MEK--ERK pathway controls ERES formation, COPII vesicle budding, and ER to Golgi transport; and (c) the ERES protein Sec16 is a target of the ERK2 pathway. Hyperactivation of the MAPK pathway increases, and its inhibition decreases ERES number. The range within which the ERES number was regulated by the MAPK pathway was 50%. Because this number is based on knockdown and not knockout conditions, the actual range in the cell may be even bigger.

A full-genome screen for regulators of secretion in *Drosophila melanogaster* cells revealed 130 hits ([@bib3]). The comparatively high number of kinases/phosphatases (122) affecting the early secretory pathway in our screen appears surprising at first sight. This difference is largely caused by the fact that the *Drosophila* screen monitored secretion of a soluble protein rather than morphological changes of the secretory pathway. Most of our kinase hits are specific to the early secretory pathway as they overlap with only 12% of hits from a screen for kinases affecting clathrin- and caveolae-mediated endocytosis (Table S2; [@bib34]).

Signaling involved in mitotic Golgi fragmentation has been elucidated in quite some detail ([@bib12]). In contrast, the role of signaling in Golgi structure regulation during interphase remains largely unknown. Mitotic Golgi fragmentation depends on signaling via MEK and ERK ([@bib42]; [@bib14]). A recent study shows that MEK to ERK signaling to the Golgi does not involve the classical MEK1/2 to ERK1/2 route. Mitotic Golgi fragmentation was mediated by a splice variant of MEK1, MEK1b, which activates a splice variant of ERK1 termed ERK1c ([@bib43]). Consistent with this observation, we have no indication for a role of ERK signaling to the Golgi in interphase cells, as treatment with EGF did not fragment the Golgi (unpublished data).

An RNAi screen was recently performed to find regulators of cell migration ([@bib45]). The library targeted 1,081 human genes encoding phosphatases, kinases, and proteins predicted to influence cell migration and adhesion. The screen identified 79 high and medium confidence genes that impaired cell migration. Because we propose that our Golgi-class hits regulate cell migration, we expected to find a considerable overlap. However, this was not the case. The only gene common to both studies is CDK4, which we found to inhibit Golgi orientation in the wound-healing assay ([Fig. 4 B](#fig4){ref-type="fig"}). However, the screen of [@bib45] failed to retrieve kinases known to regulate cell migration such as MAPK9, -10, and -14, which appeared as Golgi-class hits in our screen. These hits indicate that our collection of kinases/phosphatases required for maintaining Golgi structure is a promising resource for future studies on Golgi ribbon maintenance and its role in directional cell migration as well as in the cellular processes shown in [Fig. 3 B](#fig3){ref-type="fig"}.

How growth factors signal to the secretory pathway has been unknown. In this study, we show that growth factors signal to ERESs via the Raf--MEK--ERK pathway in an ERK2-dependent manner. Besides ERK2, upstream activators and positive modulators of ERK2, including Raf1, A-Raf, CNK1, MEKK1, and the EGF receptor, were retrieved as ER-class hits. We did not find MEK1 and -2 in our screen, most likely because of redundant signaling at this level of the MAPK pathway. The human kinome contains 20 kinases at the level of MAPK kinase kinase (MAP3K1--14, Raf1, A-Raf, B-Raf, and TAO kinases 1--3) and 14 at the level of MAPK (MAPK1 and MAPK3--15). However, there are only seven kinases at the level of MAPK kinase (MAP2K1--7). This fact points to a high degree of redundancy between different MAPK kinases. MEK1 and -2 share 85% sequence identity. Their abilities to phosphorylate ERK1 and -2 are similar, and individual deletion of MEK1 or -2 in skin fibroblasts does not reduce the amount of active ERK1/2 ([@bib40]). To the contrary, a single deletion of MEK1 seems to increase the level of active ERK1/2 ([@bib11]). In view of these considerations, it is not surprising that we did not hit MEK1/2.

We provide evidence that the effect of ERK2 on ERESs is mediated by Sec16, a major regulator of ERES homeostasis. Sec16 was directly phosphorylated by immunoprecipitated ERK and by recombinant active ERK2, most likely on T415. This residue was found to be phosphorylated in vivo ([@bib31]). Expression of a constitutively active Ras version resulted in an increase in Sec16 phosphorylation and in an increase in ERES number. This finding links the phosphorylation of Sec16 to the number of ERESs. Our combined data suggest the signaling model illustrated in [Fig. 10](#fig10){ref-type="fig"}. Although important, ERK2 may not be the only regulator of Sec16. According to the Phosida database (<http://www.phosida.com>), there are 49 sites in Sec16 that are phosphorylated, but their functional relevance is unknown. Moreover, it is worth noting that the ERES localization of Sec16 is determined by a sequence of basic amino acids in the central conserved domain of the protein ([@bib19]). The role of ERK2 is to modulate this localization in a dynamic way. Because growth factor signaling increases protein synthesis, we speculate that ERK2 adjusts ERESs to cope with this condition. In addition, environmental changes (e.g., nutrients and mitogens) can be sensed and this information transmitted via the MAPK pathway to instruct ERESs to change the rate of cargo flux.

![**Model of the pathway signaling to ERESs.** EGFR, EGF receptor.](JCB_200912082_RGB_Fig10){#fig10}

Alterations of the MAPK pathway may indirectly affect ERES number by changing the translation rate and thereby cargo load. Although we cannot entirely rule out this possibility, the following considerations argue for a direct effect. First, pharmacological inhibition of the MAPK pathway (by PD98054 for 30 min) reduced ER to Golgi transport of α1-antitrypsin ([Fig. 5 E](#fig5){ref-type="fig"}). Second, ERK2 directly stimulated COPII vesicle budding in vitro ([Fig. 6](#fig6){ref-type="fig"}). Third, pharmacological inhibition of the MAPK pathway (by PD98054 for 30 min) altered Sec16 dynamics on ERESs ([Fig. 7 A](#fig7){ref-type="fig"}). Fourth, NF1 knockdown, which hyperactivates the Raf--MEK--ERK pathway, did not induce ER stress (unpublished data). Stress induction would be expected if the increase in ERES number was a result of cargo overload ([@bib13]).

Our discovery of a link between the MAPK pathway and ER export provides a framework for a better mechanistic understanding of diseases associated with alterations of secretion. A case in point is hypersecretion of immunoglobulins observed in autoimmune disorders. ERK1 knockout mice are more prone to autoimmunity and have 10-fold higher plasma immunoglobulin levels. They display increased levels of basal ERK2 phosphorylation and thus activity ([@bib1]). We speculate that stimulation of immunoglobulin secretion is, at least in part, caused by augmented ERK2 levels. Another example is the antibody-mediated autoimmune disease systemic lupus erythematosus (SLE). Both in a mouse model of SLE and in a subset of SLE patients, a point mutation in the receptor leukocyte Tyr kinase (LTK) was identified that renders this enzyme hyperactive ([@bib28]). LTK is one of our ER-class hits, and its silencing strongly reduced the number of ERESs and ER to Golgi transport (unpublished data). It is tempting to speculate that LTK has a direct regulatory role in immunoglobulin secretion.

In conclusion, our study provides not only a resource of signaling molecules involved in the regulation of morphology and function of the secretory pathway but also uncovers growth factor signaling to ERESs via ERK2. The latter finding expands the already complex repertoire of cellular functions of ERKs and may have implications for understanding various disease states involving the MAPK pathway, including autoimmunity, cancer, and RAS/MAPK syndromes.

Materials and methods
=====================

High-throughput siRNA screening
-------------------------------

The procedure was performed essentially as described previously ([@bib34]). In brief, HeLa cells (1,000 per well) were seeded into 384-well plates and transfected 24 h later with 20 µM siRNA complexed with INTERFERin (Polyplus Transfection) as delivery agent. After 48 h, cells were fixed and labeled with 3.7% paraformaldehyde. Images were acquired using the Opera automated spinning disk confocal microscope (PerkinElmer).

FRAP microscopy
---------------

HeLa cells expressing GFP-tagged Sec16 (Addgene) or YFP-tagged Sec24D (gift from R. Pepperkok, European Molecular Biology Laboratory, Heidelberg, Germany) were cultured on glass coverslips, transferred to imaging medium 1 (Ham's F12 supplemented with 20 mM Hepes, pH 7.4) in a Ludin chamber (Life Imaging Services GmbH), and imaged with a 63× oil objective on a microscope (SP5; Leica) at room temperature. All FRAP experiments were performed by bleaching individual ERESs. A prebleaching scan was performed, and the area of interest was subsequently bleached at full laser power for 1.4 s. Pictures were taken every 1.4 s for 56 s, converted to TIF files, and analyzed using ImageJ 1.4g (National Institutes of Health). Fluorescence values of the region of interest were normalized to prebleaching values. The mobile fraction was calculated according to [@bib37] following the equation R = (*F~∞~* − *F~0~*)/(*F~i~* − *F~0~*), where *F~∞~* is fluorescence in the bleached region after recovery, *F~i~* is the fluorescence in the bleached region before bleaching, and *F~0~* is the fluorescence in the bleached region directly after bleaching.

Cell culture and transfection
-----------------------------

HeLa cells were cultured in DME containing 10% FBS and antibiotics. For gene silencing, cells cultured in 6-well plates were transfected with 5 nM siRNA using HiPerFect (QIAGEN) and typically analyzed after 72 h. cDNA transfection was performed using FuGene6 (Roche) 24 h before analysis.

Antibodies and immunofluorescence microscopy
--------------------------------------------

Monoclonal antibodies to ERGIC-53 ([@bib41]), Sec31 (BD), and GFP (Roche) were used. Rabbit antibodies to giantin (gift of A. Linstedt, Carnegie Mellon University, Pittsburgh, PA), Sec24A and -B (gift of J.-P. Paccaud, Drugs for Neglected Diseases Initiative, Geneva, Switzerland), Sec31 (gift of F. Gorelick, Yale University, New Haven, CT; [@bib44]), ERK1/2, phosphorylated ERK1/2, MAPK substrate, PKC substrate (Cell Signaling Technology), Sec16 ([@bib18]), Sec24D ([@bib48]), and XBP1s (BioLegend) were also used. FITC--Con A was obtained from Invitrogen. HeLa cells were fixed with 3% paraformaldehyde, pH 7.4, for 30 min at room temperature, permeabilized for 4 min with PBS supplemented with 20 mM Gly, 0.2% Triton X-100, and 3% bovine serum albumin, and stained with antibodies. Images were acquired with a confocal microscope (SPE; Leica) using a 40× oil objective. For counting peripheral ERGIC clusters and ERESs, images were acquired with an additional 1.5 magnification in one confocal plane with a thickness of typically 210 nm. The raw images were converted to TIF files and analyzed using ImagePro Plus software (Media Cybernetics). Anti-Sec31--labeled ERESs were defined as bright objects in the top 80% of the intensity scale with a diameter of \>1.5 pixels. This evaluation allows exclusion of objects that are too dim and too small and thereby avoids counting false objects that may occur as the result of the pixelization of images. Alternatively, ERESs were counted using ImageJ. Here, all circular objects were analyzed. The threshold was set individually for every image to assure that only true ERESs were counted. Both methods produced very similar results. For the counting of ERESs, 25--84 cells were evaluated per condition, and three independent experiments were performed. In experiments dealing with transfected GFP-Sec16, we only chose moderately expressing cells. Here, we used 10--19 cells per condition in three independent experiments.

Pulse-chase experiments
-----------------------

HeLa cells (2 × 10^5^ in 2.5-cm dishes) were transfected with 5 nM siRNA. Pulse-chase experiments were performed 72 h after transfection. Cells were incubated in Met-free DME (supplemented with Gln and dialyzed FBS) for 20 min and pulsed in medium containing \[^35^S\]Met (100 µCi/dish) for 10 min. The medium was then replaced by complete DME containing 10 mM nonlabeled Met. Cells were lysed after different chase times and subjected to immunoprecipitation.

Vesicle budding assay
---------------------

The following buffers were used: buffer E (50 mM Hepes-KOH, pH 7.2, 250 mM sorbitol, 70 mM KOAc, 5 mM EDTA, and 0.5 mM MgOAc), buffer F (10 mM Hepes-KOH, pH 7.2, 250 mM sorbitol, 10 mM KOAc, and 1.5 mM MgOAc), and buffer G (20 mM Hepes-KOH, pH 7.2, 250 mM sorbitol, 140 mM KOAc, and 0.5 mM MgOAc). The method of [@bib23] was used and adapted as follows. The preparation of cytosol and microsomes was performed at 4°C. Cytosol was prepared from HeLa cells (six 10-cm dishes) that were knocked down for ERK2. Cells were scraped into 2 ml of buffer E and centrifuged at 500 *g* for 10 min. The cell pellet was resuspended in 50 µl per 10-cm dish of buffer E. Cells were passed through a 25-gauge syringe at least 30 times and centrifuged at 1,000 *g* for 10 min. The postnuclear supernatant was centrifuged at 100,000 *g* for 30 min. The supernatant was used as cytosol. It had a mean protein concentration of 2--2.5 mg/ml. For the preparation of microsomes, cells of three 10-cm dishes were scraped into 1 ml PBS and centrifuged at 500 *g* for 10 min. The pellet was resuspended in 400 µl of buffer F. Cells were passed through a 25-gauge syringe at least 30 times and centrifuged at 1,000 *g* for 10 min. The postnuclear supernatant was centrifuged at 6,000 *g* for 10 min. The pellet was resuspended in 400 µl of buffer G and recentrifuged at 6,000 *g* for 10 min at 4°C. The pellet was resuspended in 96 µl of buffer G. For a typical budding reaction, 30 µl of microsomes and 65 µl of cytosol were used. The reaction mixture contained 0.5 mM GTP (Sigma-Aldrich) and an ATP regeneration system (1 mM ATP, 25 mM creatine phosphate, and 0.3 mg/ml creatine kinase; Sigma-Aldrich). The reaction was performed for 30 min at 25°C or on ice (control). In the ERK2-containing reactions, 100 ng recombinant active ERK2 (activated by purifying from cells expressing constitutive active MEK1; Cell Signaling Technology) was added. The reaction was terminated by transferring the tubes to ice. Microsomes were collected by centrifugation at 16,000 *g* for 10 min. The supernatant was centrifuged at 100,000 *g* for 40 min to pellet the budded vesicles. Budding efficiency was calculated as (V/M~ERGIC-53~ × 100) − (V/M~CLIMP63~ × 100). To show that the budding assay for ERGIC-53 is COPII dependent, we performed budding assays with cytosol immunodepleted for Sec24A and -B ([@bib48]).

Immunoprecipitation
-------------------

For each immunoprecipitation experiment with GFP-tagged Sec16, three 10-cm dishes (70% confluent cells) were used. Cells were transfected with GFP-tagged Sec16 cDNA. After 24 h, cells were lysed in 800 µl of immunoprecipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM CaCl~2~, and 1% Triton X-100). The lysate was incubated on ice for 10 min and cleared by centrifugation at 16,000 *g* for 10 min at 4°C. To the cleared lysate, protein G--Sepharose was added to which anti-GFP antibody had been preadsorbed. This mixture was incubated overnight with gentle agitation at 4°C. On the next day, the beads were washed three times, and Sec16 was eluted by boiling in sample buffer. For the kinase assay, the beads were washed thrice with kinase buffer (Cell Signaling Technology) and finally resuspended in 30 µl of this buffer.

Mutagenesis of Sec16
--------------------

The following primer pair was used (the mutated triplet is underlined and bold): Thr415Ile, 5′-CGTGTCCCAGCCCTCA**[ATT]{.ul}**CCGAGCCCCCCG-3′ and 5′-CGGGGGGCTCGG**[AAT]{.ul}**TGAGGGCTGGGACACG-3′. A two-step PCR mutagenesis method was used. Two PCR reactions were performed in parallel, each containing only one primer. A typical PCR mixture (50 µl volume) contained 1 µl DNA (50 ng final), 1 µl Pfu polymerase, 5 µl of 10× buffer, 4 µl of primer (0.8 µM final concentration), 4 µl dNTP mixture (0.2 µM final concentration), and 35 µl water. The first PCR reaction was performed for 10 cycles (60 s at 95°C, 90 s at 55°C, and 21 min at 68°C). 25 µl of each reaction was then pooled, and 0.7 µl Pfu polymerase was added. The second PCR reaction was performed for 18 cycles with the same conditions. PCR products were digested with DpnI for 3 h at 37°C and used to transform *Escherichia coli*. On the next day, colonies were picked and grown in 3-ml cultures overnight. 1 d later, plasmids were prepared using the GenElute Plasmid Miniprep kit (Sigma-Aldrich). All mutations were verified by sequencing.

Statistics
----------

All data analysis was performed using Excel2003 (Microsoft). Error bars on all graphs are mean ± SD from three independent measurements, except where indicated otherwise in the figures. Statistical significance was calculated using the *t* test, and P \< 0.05 was considered significant.

Bioinformatic analysis
----------------------

Interaction networks were generated using the STRING database. Only interactions supported by biochemical evidence or databases (including Kyoto Encyclopedia of Genes and Genomes, Reactome, and Pathway Interactin Database) were considered. Anchored networks were created using the Cytoscape software (version 2.6.3; <http://cytoscape.org/>) using an algorithm described by [@bib50]. The following parameters were used when a BiNGO analysis (of *Homo sapiens* GO annotations) was performed: hypergeometric test, Benjamini-Hochberg false discovery rate correction (to correct for multiple testing), significance value 0.001, and GO biological processes. Each cluster was tested against the whole annotation.

Online supplemental material
----------------------------

Fig. S1 shows the distribution of ER-, mixed-, and Golgi-class hits in several signaling pathways. Fig. S2 shows the impact of NF1 or CNK1 knockdowns on ERK1/2 activation. Fig. S3 shows the effect of Sec24A+B depletion or ERK1 on budding of ERGIC-53. Table S1, included as an Excel file, contains a list of all kinases phosphatases that have been targeted and the ID numbers of the siRNAs that were used to target them. Table S2, included as an Excel file, contains a list of all 122 hits classified into ER-, mixed-, and Golgi-class hits and information about tubulin staining and the effect on the number of peripheral ERGIC punctae and cites evidence for the expression of the gene in HeLa cells. A zip file contains large PDF versions of the networks in [Fig. 3](#fig3){ref-type="fig"} and their underlying data (which can be opened and visualized in Cytoscape). Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200912082/DC1>.
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